BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 28323826)

  • 1. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts.
    Qian J; Wolters FJ; Beiser A; Haan M; Ikram MA; Karlawish J; Langbaum JB; Neuhaus JM; Reiman EM; Roberts JS; Seshadri S; Tariot PN; Woods BM; Betensky RA; Blacker D
    PLoS Med; 2017 Mar; 14(3):e1002254. PubMed ID: 28323826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.
    Scarabino D; Broggio E; Gambina G; Maida C; Gaudio MR; Corbo RM
    Am J Med Genet B Neuropsychiatr Genet; 2016 Dec; 171(8):1131-1138. PubMed ID: 27604972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study.
    van der Lee SJ; Wolters FJ; Ikram MK; Hofman A; Ikram MA; Amin N; van Duijn CM
    Lancet Neurol; 2018 May; 17(5):434-444. PubMed ID: 29555425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of the APOE ε2ε4 Genotype on the Development of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) in Non-Latino Whites.
    Ren D; Lopez OL; Lingler JH; Conley Y
    J Am Geriatr Soc; 2020 May; 68(5):1044-1049. PubMed ID: 32017008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative health deficits,
    Ward DD; Wallace LMK; Rockwood K
    J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):136-142. PubMed ID: 33188132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of neural compensatory mechanisms of BDNF val66met met carriers and APOE E4 carriers in healthy aging, mild cognitive impairment, and Alzheimer's disease.
    Gomar JJ; Conejero-Goldberg C; Huey ED; Davies P; Goldberg TE;
    Neurobiol Aging; 2016 Mar; 39():165-73. PubMed ID: 26923413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder.
    Kerr DS; Stella F; Radanovic M; Aprahamian I; Bertollucci PH; Forlenza OV
    Bipolar Disord; 2016 Feb; 18(1):71-7. PubMed ID: 26877211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
    Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
    BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's disease.
    Caputo A; Racine A; Paule I; Tariot PN; Langbaum JB; Coello N; Riviere ME; Ryan JM; Lopez CL; Graf A; ;
    Alzheimers Res Ther; 2023 Mar; 15(1):45. PubMed ID: 36879340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE ε4 Genotype.
    Krell-Roesch J; Vemuri P; Pink A; Roberts RO; Stokin GB; Mielke MM; Christianson TJ; Knopman DS; Petersen RC; Kremers WK; Geda YE
    JAMA Neurol; 2017 Mar; 74(3):332-338. PubMed ID: 28135351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.
    Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E;
    Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study.
    Gharbi-Meliani A; Dugravot A; Sabia S; Regy M; Fayosse A; Schnitzler A; Kivimäki M; Singh-Manoux A; Dumurgier J
    Alzheimers Res Ther; 2021 Jan; 13(1):5. PubMed ID: 33397450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative.
    Dunk MM; Driscoll I;
    J Alzheimers Dis; 2022; 85(4):1519-1528. PubMed ID: 34958023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related cognitive decline and associations with sex, education and apolipoprotein E genotype across ethnocultural groups and geographic regions: a collaborative cohort study.
    Lipnicki DM; Crawford JD; Dutta R; Thalamuthu A; Kochan NA; Andrews G; Lima-Costa MF; Castro-Costa E; Brayne C; Matthews FE; Stephan BC; Lipton RB; Katz MJ; Ritchie K; Scali J; Ancelin ML; Scarmeas N; Yannakoulia M; Dardiotis E; Lam LC; Wong CH; Fung AW; Guaita A; Vaccaro R; Davin A; Kim KW; Han JW; Kim TH; Anstey KJ; Cherbuin N; Butterworth P; Scazufca M; Kumagai S; Chen S; Narazaki K; Ng TP; Gao Q; Reppermund S; Brodaty H; Lobo A; Lopez-Anton R; Santabárbara J; Sachdev PS;
    PLoS Med; 2017 Mar; 14(3):e1002261. PubMed ID: 28323832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects.
    Engelborghs S; Dermaut B; Goeman J; Saerens J; Mariën P; Pickut BA; Van den Broeck M; Serneels S; Cruts M; Van Broeckhoven C; De Deyn PP
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1148-51. PubMed ID: 12876259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants, MRI correlates, and prognosis of mild cognitive impairment: the Rotterdam Study.
    de Bruijn RF; Akoudad S; Cremers LG; Hofman A; Niessen WJ; van der Lugt A; Koudstaal PJ; Vernooij MW; Ikram MA
    J Alzheimers Dis; 2014; 42 Suppl 3():S239-49. PubMed ID: 24825566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subjective cognitive decline, APOE e4 allele, and the risk of neurocognitive disorders: Age- and sex-stratified cohort study.
    Liew TM
    Aust N Z J Psychiatry; 2022 Dec; 56(12):1664-1675. PubMed ID: 35229693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dementia and cognitive impairment pattern: its association with epsilon4 allele of apolipoprotein E gene].
    Rosich-Estragó M; Figuera-Terré L; Mulet-Pérez B; Arrufat-Cardús MT; Pascual San Emeterio A; Arbeola-Rigau I; Labad-Alquézar A; Vilella-Cuadrada E
    Rev Neurol; 2004 May 1-15; 38(9):801-7. PubMed ID: 15152345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-Year Change in Body Mass Index Predicts Conversion to Mild Cognitive Impairment or Dementia Only in APOE ɛ4 Allele Carriers.
    Kadey KR; Woodard JL; Moll AC; Nielson KA; Smith JC; Durgerian S; Rao SM
    J Alzheimers Dis; 2021; 81(1):189-199. PubMed ID: 33749649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.